Skip to main content

Table 1 The demographic features and NfL concentration in Cohort A and B

From: Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3

Group Cohort A Cohort B
Control SCA3 Control1 Preclinical SCA3 Control2 Manifest SCA3
n 9 17 21 26 70 90
Age 54.33 ± 11.69 49.88 ± 11.75 31.62 ± 11.61 31.38 ± 9.30 43.13 ± 12.66 43.90 ± 12.16
Sex (M/F) 4/5 6/11 8/13 9/17 31/39 41/49
Expanded CAG repeats N/A 73.18 ± 3.64 N/A 72.62 ± 4.97 N/A 73.91 ± 4.04
SARA N/A 13.82 ± 5.56 N/A 0.73 ± 0.83 N/A 11.72 ± 6.02
ICARS N/A 35.00 ± 11.06 N/A 1.81 ± 1.81 N/A 29.04 ± 13.90
Disease duration (ys) N/A 5.82 ± 3.56 N/A N/A N/A 6.59 ± 5.53
Total intracranial volume (mL) N/A N/A N/A 1416.00 ± 128.60 (n = 2) N/A 1496.00 ± 231.20 (n = 66)
Cerebellum (mL) N/A N/A N/A 148.17 ± 87.77 (n = 2) N/A 127.07 ± 21.27 (n = 66)
Brainstem (mL) N/A N/A N/A 22.17 ± 1.38 (n = 2) N/A 20.05 ± 4.66 (n = 66)
Serum NfL (pg/mL) 9.10 ± 3.29 41.50 ± 14.78 6.88 ± 2.72 15.03 ± 7.49 9.07 ± 6.02 37.56 ± 13.47
CSF NfL (pg/mL) 471.70 ± 210.40 4262.00 ± 1762.00 N/A N/A N/A N/A
  1. Values are mean ± SD. SARA Scale for the assessment and rating of ataxia, ICARS International cooperative ataxia rating scale, N/A Not applicable